Subsequent Events (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 14, 2026 |
Aug. 04, 2026 |
Jul. 24, 2026 |
Jul. 14, 2026 |
Jul. 08, 2026 |
Sep. 11, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jan. 03, 2025 |
|
| Subsequent Event [Line Items] | ||||||||||||
| Commitment warrant | $ (107,000) | $ 3,376,000 | $ (1,000) | |||||||||
| Aggregate gross proceeds | $ 1,000 | |||||||||||
| Exchange Agreement [Member] | Note Investor [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Principal amount | $ 833,000 | |||||||||||
| Note exchange value | $ 900,000 | $ 900,000 | ||||||||||
| Number of shares exchanged | 2,859,701,000 | |||||||||||
| Common Stock [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Number of shares, value | $ 20,000,000.0 | |||||||||||
| Sale of stock shares | 1,480,000 | 2,060,000 | ||||||||||
| Net proceeds | $ 1,102,000 | $ 1,692,000 | ||||||||||
| Warrant [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Commitment warrant | $ 107,000 | $ 3,269,000 | ||||||||||
| Warrants to purchase shares | 108,064 | |||||||||||
| Subsequent Event [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Minimum price | $ 0.01 | |||||||||||
| Sale of stock shares | 300,000 | |||||||||||
| Net proceeds | $ 92,000 | |||||||||||
| Subsequent Event [Member] | Bridge Notes [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Exercisable warrants term | 5 years | |||||||||||
| Issuance of exercise | $ 35,000 | |||||||||||
| Subsequent Event [Member] | Purchase Agreement and Security Agreement [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Gross proceeds | $ 3,500,000 | |||||||||||
| Principal amount | 4,487,000 | |||||||||||
| Original issue discount | $ 3,081,000 | |||||||||||
| Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | White Lion Capital LLC [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Minimum price | $ 0.39912 | |||||||||||
| Percentage of shares outstanding | 4.99% | |||||||||||
| Percentage of beneficial ownership limitation | 9.99% | |||||||||||
| Commitment fee amount | $ 1,000 | |||||||||||
| Liquidated damages | 250,000 | |||||||||||
| Additional liquidated damages | 50,000 | |||||||||||
| Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Maximum [Member] | White Lion Capital LLC [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Number of shares, value | $ 50,000 | |||||||||||
| Percentage of shares outstanding | 19.99% | |||||||||||
| Commitment warrant | $ 1,000 | |||||||||||
| Subsequent Event [Member] | Common Stock [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Number of shares issued | 1,159,842 | |||||||||||
| Number of shares not yet been issued | 151,358 | |||||||||||
| Minimum price | $ 1.1597 | |||||||||||
| Subsequent Event [Member] | Preferred Stock [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Number of shares issued | 694,679 | |||||||||||
| Number of shares not yet been issued | 90,655 | |||||||||||
| Minimum price | $ 0.6946 | |||||||||||
| Subsequent Event [Member] | Warrant [Member] | Common Stock Purchase Agreement [Member] | Maximum [Member] | White Lion Capital LLC [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Commitment warrant | $ 10,000 | |||||||||||
| Subsequent Event [Member] | Prefunded Warrants [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Number of shares issued | 2,666,667 | |||||||||||
| Warrants to purchase shares | 2,666,667 | |||||||||||
| Warrants exercise price | $ 0.75 | |||||||||||
| Shares issued price per share | $ 0.0001 | |||||||||||
| Subsequent Event [Member] | Warrant Shares [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Warrants to purchase shares | 2,666,667 | |||||||||||
| Warrants exercise price | $ 1.50 | |||||||||||
| Aggregate gross proceeds | $ 2,000,000 | |||||||||||
| Lokahi Therapeutics Inc [Member] | Subsequent Event [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Description of shares issued and outstanding | (i) each share of common stock of Merger Sub, issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and nonassessable share of common stock of Lokahi; and (ii) each share of Existing Lokahi Common Stock issued and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive a portion of the Merger Consideration (as defined below), consisting of (A) shares of Common Stock, such that the aggregate number of shares of Common Stock issued to all holders of Existing Lokahi Common Stock equaled 19.99% of the total number of shares of Common Stock issued and outstanding as of the date of the Merger Agreement, and (B) shares of Series A convertible preferred stock, par value $0.001 per share, of the Company (the “Preferred Stock”), with each holder of such shares receiving, for each share of Existing Lokahi Common Stock held immediately prior to the Effective Time, a pro rata portion of the Merger Consideration, such that, immediately following the Effective Time, the holders of Existing Lokahi Common Stock collectively hold, on a fully-diluted and as-converted to Common Stock basis, 90.0% of the total issued and outstanding equity securities of the Company calculated on a fully diluted basis (the “Lokahi Allocation”); provided, however, that any dilution attributable to Bridge Shares (as defined in the Merger Agreement) and PIPE Shares (as defined in the Merger Agreement) shall be borne solely by the Lokahi Allocation, such that the Company’s existing stockholders shall, in no event, hold less than 10.0% of the total issued and outstanding equity securities of the Company on a fully diluted basis immediately following the Effective Time (the “Stockholder Floor”). | |||||||||||
| Lokahi Therapeutics Inc [Member] | Subsequent Event [Member] | Merger Agreement [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Subsidiary contribution, description | Pursuant to the Merger Agreement, an aggregate of $7,000 shall be deposited into an account designated by Glucotrack Technologies and released to Glucotrack Technologies in installments as follows (the “Subsidiary Contribution”): (i) $500 on Closing; (ii) $1,500 concurrently with the PIPE Initial Closing; (iii) $1,500 upon the earliest to occur of (A) the Company’s receipt of notice or a decision from Nasdaq confirming satisfaction of the Nasdaq continued listing requirements or granting a grace period, (B) the official closing price of the Common Stock on Nasdaq exceeding $1.25 per share for three (3) consecutive trading days, or (C) August 30, 2026; (iv) $2,000 simultaneously with (or promptly following) the filing of the preliminary Proxy Statement with the SEC; and (v) $1,500 simultaneously with (or promptly following) the Conversion Effective Time. In addition to the Subsidiary Contribution, Glucotrack Technologies shall retain all cash and cash equivalents on the balance sheet of the Company as of the Closing Date. | |||||||||||
| Percentage of outstanding equity of the Acquiror | 10.00% | |||||||||||
| Gross proceeds | $ 4,450,000 | |||||||||||
| Description of registration rights | The Company is required to use commercially reasonable efforts to cause such registration statement to be declared effective within forty-five (45) days of the closing date of the Bridge Financing (the “Required Effective Registration Date”). If the registration statement is not declared effective by the Required Effective Registration Date, the Company shall issue and deliver to the Bridge Investors a number of shares of Common Stock equal to $250 divided by the lowest traded price of the Common Stock between the closing of the Bridge Financing and the Required Effective Registration Date, and for every thirty (30) days thereafter that the registration statement is not declared effective, the Company shall issue and deliver to the Bridge Investors a number of additional shares of Common Stock equal to $250 divided by the lowest traded price of the Common Stock during such thirty (30) day period. | |||||||||||
| Description of bridge stock holder approval | Within thirty (30) days of the closing date of the Bridge Financing (the “Required Initial Proxy Date”), the Company was required to file a proxy statement with the SEC for the purpose of obtaining stockholder approval for the issuance of shares of Common Stock in excess of 19.99% of the outstanding Common Stock pursuant to the Bridge Financing Documents in accordance with Nasdaq Listing Rule 5635(d) (the “Bridge Stockholder Approval”). The Company is required to use commercially reasonable efforts to obtain the Bridge Stockholder Approval within sixty (60) days of the closing date (the “Required Stockholder Meeting Date”). For every thirty (30) days after the Required Stockholder Meeting Date that the stockholder meeting is not held, the Company shall issue and deliver to the Bridge Investors a number of additional shares of Common Stock equal to $250 divided by the lowest traded price of the Common Stock during such thirty (30) day period. If the Bridge Stockholder Approval is not obtained by the first Required Stockholder Meeting Date, the Company is required to cause an additional stockholder meeting to be held every sixty (60) days during the period beginning on such date and continuing 360 days thereafter until the Bridge Stockholder Approval is obtained. | |||||||||||
| Lokahi Therapeutics Inc [Member] | Subsequent Event [Member] | Merger Agreement [Member] | Bridge Notes [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Percentage of original issue discount rate | 22.00% | |||||||||||
| Interest rate | 8.00% | |||||||||||
| Description of maturity | mature nine (9) months from the date of issuance | |||||||||||
| Debt conversion description | The Bridge Notes are convertible, following Bridge Stockholder Approval, at a conversion price equal to the lower of (i) the Nasdaq Minimum Price (as defined in the Purchase Agreement) and (ii) 80% of the lowest daily volume weighted average price of the Common Stock during the fifteen (15) trading days immediately preceding the conversion notice, subject to a floor price equal to 20% of the Nasdaq Minimum Price as of the date of issuance of the Bridge Notes. | |||||||||||
| Lokahi Therapeutics Inc [Member] | Subsequent Event [Member] | Merger Agreement [Member] | Maximum [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Aggregate amount of private placement | $ 30,000 | |||||||||||
| Lokahi Therapeutics Inc [Member] | Subsequent Event [Member] | Merger Agreement [Member] | Minimum [Member] | ||||||||||||
| Subsequent Event [Line Items] | ||||||||||||
| Gross aggregate amount of private placement | $ 10,000 | |||||||||||